WilmerHale represented Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company, in connection with its underwritten public offering of 24,150,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 3,150,000 shares of common stock, at a public offering price of $3.80 per share. The gross proceeds to Infinity were approximately $91.8 million, before deducting underwriting discounts and offering expenses. The offering priced on February 12, 2021 and closed on February 17, 2021.

The WilmerHale team representing Infinity was led by Cynthia Mazareas, and included Stephanie Leopold, Jason Hyatt, Taylor Gibson, Meghan Muncey and Elijah Soko.

For more information, read Infinity’s press release.